Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

Summary

This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.

Timeline

Start

2025-02-13

Primary completion

2025-11-17

Completion

2025-11-17

Outcome

Met primary endpoint

release “EVO301 met the trial’s primary endpoint, achieving a 55% least-squares (LS) mean reduction in EASI from baseline at Week 12” evommune.com ↗

Drugs

Indications